Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.pfizer.ca
Number of Employees: 1,000
Year Founded: 1953
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Pfizer Canada Inc. operates as a biopharmaceutical company that discovers and develops vaccines, infusion systems, and non-prescription products in Canada. The company offers prescription pharmaceutical products in the areas of analgesic and anti-inflammatory, anti-infective, cardiovascular and oncology, endocrinology, GI and GU, HIV, immunosuppressant, men and women's health, neurological, ophthalmology, urology, and other areas. It also provides non-prescription products, including oral and external analgesics, cough and cold remedies, topical products, dietary supplements, and antifungals; and vaccines for polio, diphtheria, mumps, and measles. Pfizer Canada Inc. sells products through wholesalers, group purchasing organizations, pharmacy chains and banners, and pharmacies. The company was founded in 1953 and is based in Kirkland, Canada with a manufacturing location in Brandon, Canada. Pfizer Canada Inc. operates as a subsidiary of Pfizer Inc.


Financial Information (Currency: CAD, in mm)
Total Revenue
 455.5
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 1,000
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Helou, John 
President
Sampson, Najah 
President
Monteleone, Frank P.
Vice President of Legal Affairs
Simmons, David
Vice President of Marketing


Primary Industry Classification
Pharmaceuticals


Primary Office Location
17300 Trans-Canada Highway | Kirkland, QC | H9J 2M5 | Canada
Fax: 514 426 6997

Parent Company
Pfizer Inc. (NYSE:PFE)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-31-2007
Dec-31-2007
Merger/Acquisition
Seller
Pfizer Canada, Inc., Manufacturing Facility in Arnprior, Ontario
KEATA Pharma, Inc.
Pfizer Canada Inc.
5.59
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-28-2023
Product-Related Announcements
Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine
Dec-09-2022
Product-Related Announcements
Pfizer and BioNTech SE Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age
Oct-07-2022
Product-Related Announcements
Pfizer Canada ULC and BioNTech SE's Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Individuals 12 Years of Age and Older
Jul-21-2022
Product-Related Announcements
Pfizer Announces PREVNAR 20™ (Pneumococcal 20-Valent Conjugate Vaccine) Is Now Available in Canada for the Prevention of Pneumonia and Invasive Pneumococcal Disease in Adults 18 Years of Age and Older
May-16-2022
Executive Changes - CEO
Pfizer Canada Inc. Announces Management Changes

Competitors
Apotex Inc., AstraZeneca Canada Inc., Bayer Inc., Bristol Myers Squibb Canada Co., GlaxoSmithKline Inc., Janssen Inc., Johnson & Johnson Inc., Merck Canada Inc., Novartis Pharmaceuticals Canada Inc., Pharmascience Inc., Sandoz Canada Inc., Teva Canada Limited, Valeant Canada Ltd., Viatris Inc. (NasdaqGS:VTRS)


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 18, 2023 02:41 AM
Pfizer Canada Inc.
Pfizer Canada Inc
Reports
47
GlobalData

Jun 20, 2023 01:30 AM
Pfizer Canada Inc.
Pfizer Canada Inc
Reports
47
GlobalData

Mar 16, 2023 03:41 AM
Pfizer Canada Inc.
Pfizer Canada Inc
Reports
44
GlobalData

Dec 18, 2022 11:47 PM
Pfizer Canada Inc.
Pfizer Canada Inc
Reports
44
GlobalData

Sep 23, 2022 05:47 AM
Pfizer Canada Inc.
Pfizer Canada Inc
Reports
42
GlobalData

Jun 28, 2022 12:09 AM
Pfizer Canada Inc.
Pfizer Canada Inc
Reports
40
GlobalData

Mar 29, 2022 06:35 AM
Pfizer Canada Inc.
Pfizer Canada Inc
Reports
40
GlobalData

Dec 13, 2021 02:28 AM
Pfizer Canada Inc.
Pfizer Canada Inc
Reports
28
GlobalData

Sep 15, 2021 02:59 AM
Pfizer Canada Inc.
Pfizer Canada Inc
Reports
19
GlobalData

Jun 15, 2021 08:20 PM
Pfizer Canada Inc.
Pfizer Canada Inc
Reports
21


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
CELSENTRI Tablets, ERAXIS, INSPRA, Lipitor, Revatio, Toviaz, TRUMENBA, XALKORI, XYNTHA Solofuse, Zmax SR


Upcoming Events
Date/Time
Type
Oct-21-2023
Conferences
Oct-24-2023
Conferences
Oct-24-2023 1:45 PM (EDT)
Company Conference Presentations
* Future Events are subject to change.

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Helou, John 
President
-
514 426 6997

Sampson, Najah 
President
-
514 426 6997

Monteleone, Frank P.
Vice President of Legal Affairs
-
514 426 6997
-
Simmons, David
Vice President of Marketing
-
514 426 6997
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
